Abstract
As human phosphodiesterase (PDE) proteins are attractive drug targets, a large number of selective PDE inhibitors have been developed. However, since the catalytic sites of PDE isoforms are conserved in sequence and structure, it remains unclear how these inhibitors discriminate PDE isoforms in a selective manner. Here we perform long-time scale molecular dynamics (MD) simulations to investigate the spontaneous association processes of a highly selective PDE2A inhibitor (BAY60–7550) with the catalytic pockets of six PDE isoforms. We found that the free-energy landscapes of PDE:BAY60–7550 interactions on the PDE surfaces are very different between various PDE isoforms; and the free-energy landscape of PDE2A forms a favorable low-energy pathway that not only drives BAY60–7550 toward the target binding site, but also guides BAY60–7750 to adopt its native binding conformation known from crystal structure. Thus, this study reveals that the inhibitor interactions with the PDE surface residues play an important role in its high selectivity for PDE2A, and thereby provides new fundamental insights into the PDE isoform-specific inhibitor selectivity.
Highlights
Human phosphodiesterase (PDE) family consists of 11 subfamilies and expressed in a tissue-specific manner [1]
We used the root-mean-square deviation (RMSD) to evaluate the similarity between the PDE-bound conformations of BAY60– 7550 in the molecular dynamics (MD) simulations and the native pose [11]
We have performed unbiased MD simulations to successfully capture the spontaneous associations of BAY60–7550 with the catalytic pockets of the 6 PDE isoforms
Summary
Human phosphodiesterase (PDE) family consists of 11 subfamilies and expressed in a tissue-specific manner [1]. In the past two decades, many PDE inhibitors have been developed, including sildenafil (PDE5 inhibitor) [5], roflumilast (PDE4 inhibitor) [6], and milrinone (PDE3 inhibitor) [7], which were approved for the treatments of erectile dysfunction [8], chronic obstructive pulmonary disease (COPD) [6], and congestive heart failure [9], respectively. Those PDE inhibitors could cause side effects during their clinical treatments. Because the binding selectivity of the PDE inhibitors is crucial for the development of safe drugs, it is necessary to fully understand the structural origins of the PDE inhibitor selectivity
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Computational and Structural Biotechnology Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.